172 Results

People

  1. Motzer
    Motzer
  2. Abrey
    Abrey
  3. De Angelis
    De Angelis
  4. Riely
    Riely
  5. Abou-Alfa
    Abou-Alfa
  6. Kelly
    Kelly
  7. Scher
    Scher
  8. Drilon
    Drilon
  9. Feldman
    Feldman
  10. Ginsberg
    Ginsberg

Groups

  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)
  7. Biostatistics Service (27)
  8. Thoracic Oncology (19)
  9. Division of Subspecialty Medicine (18)
  10. GSK Faculty (18)
  1. "hypophosphatemia"
Formats
  1. Journal Article (160)
  2. Review (7)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)

More Groups

People
  1. Robert Motzer (18)
  2. Lauren Abrey (9)
  3. Lisa De Angelis (8)
  4. Gregory Riely (7)
  5. Ghassan Abou-Alfa (6)
  6. Howard Scher (6)

More People

Years
  1. 2025 (8)
  2. 2024 (13)
  3. 2023 (13)
  4. 2022 (7)
  5. 2021 (4)
  6. 2020 (21)

More Years

Publications
  1. Lancet Oncology (16)
  2. Cancer (11)
  3. Clinical Cancer Research (11)
  4. Journal of Clinical Oncology (10)
  5. New England Journal of Medicine (10)
  6. Neuro-Oncology (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (25)
  2. Elsevier Inc. (19)
  3. American Association for Cancer Research (12)
  4. Wiley Blackwell (12)
  5. Oxford University Press (11)
  6. Springer (11)

More Publishers

Results (172)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results: CHRONIC MYELOID LEUKEMIA
    Journal Article

    Hochhaus, A.; Kim, D. W.; Cortes, J. E.; Sasaki, K.; Mauro, M. J.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: A first-in-human, single-centre, phase 1 trial
    Journal Article

    Lou, E.; Choudhry, M. S.; Starr, T. K.; Folsom, T. D.; Bell, J.; Rathmann, B.; DeFeo, A. P.; Kim, J.; Slipek, N.; Jin, Z.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies
    Journal Article

    Lopez, J. S.; Milhem, M.; Butler, M. O.; Thistlethwaite, F.; Van Tine, B. A.; D'Angelo, S. P.; Johnson, M. L.; Sato, T.; Arkenau, H. T.; Edukulla, R.; more...
    Cell Reports Medicine (2025)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
    Research Letter

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A.; Sallman, D.; Patel, M.; Stevens, D.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
    Journal Article

    Scott, S. C.; Farago, A.; Lai, W. V.; Zahurak, M.; Rudek, M. A.; Murray, J.; Carducci, M. A.; Uziel, T.; Takebe, N.; Gore, S. D.; more...
    Cancer Chemotherapy and Pharmacology (2025)

    Fulltext@MSK | Save
  • MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Journal Article

    Bhutani, M.; Robinson, M.; Foureau, D.; Atrash, S.; Paul, B.; Guo, F.; Grayson, J. M.; Ivanina-Foureau, A.; Pineda-Roman, M.; Varga, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma
    Review

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Phase II study of palbociclib in patients with tumors with CDK4 or CDK6 amplification: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1C
    Journal Article

    O’Hara, M. H.; Jegede, O.; Dickson, M. A.; DeMichele, A. M.; Piekarz, R.; Gray, R. J.; Wang, V.; McShane, L. M.; Rubinstein, L. V.; Patton, D. R.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Phase 2 trial of regorafenib in recurrent/metastatic adenoid cystic carcinoma
    Journal Article

    Desilets, A.; Vos, J. L.; Katabi, N.; Kuo, F.; Nadeem, Z.; Linxweiler, M.; Ostrovnaya, I.; Baxi, S.; Dunn, L. A.; Sherman, E. J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Role of artificial intelligence in critical care nutrition support and research
    Review

    Kittrell, H. D.; Shaikh, A.; Adintori, P. A.; McCarthy, P.; Kohli-Seth, R.; Nadkarni, G. N.; Sakhuja, A.
    Nutrition in Clinical Practice (2024)

    Fulltext@MSK | Save